

Drugs Misuse Prevention Committee meeting

Date: 17/12/15

Location: NICE London office, Derwent Room
10 Spring Gardens, London, SW1A 2BU

Minutes: Final

Committee members present:	
David Croisdale-Appleby (Chair)	(Present for notes 1 – 12)
Janis Baird (Core)	(Present for notes 1 – 11)
Ross Cowan (Community Core)	(Present for notes 1 – 12)
Hiten Dodhia (Core)	(Present for notes 1 – 11)
Rose Durban (Core)	(Present for notes 2 – 12)
Eileen Kaner (Core)	(Present for notes 4 – 12)
Stephen Morris (Core)	(Present for notes 6 – 12)
Kamran Siddiqi (Core)	(Present for notes 1 – 11)
Rachel Bundock (Topic Expert)	(Present for notes 1 – 12)
Blaine Stothard (Topic Expert)	(Present for notes 1 – 12)
Paul McArdle (Topic Expert)	(Present for notes 1 – 12)
Jim McCambridge (Topic Expert)	(Present for notes 1 – 12)
April Wareham (Community Topic Expert)	(Present for notes 1 – 12)

In attendance:		
Adrienne Cullum	Technical Lead, NICE	(Present for items 1 – 12)
Ella Novakovic	Senior Technical Analyst, NICE	(Present for items 1 – 12)
Thomas Hudson	Information Specialist, NICE	(Present for items 1 – 12)
Ian Wall	Assistant Project Manager, NICE	(Present for items 1 – 12)
Geoff Bates	Liverpool University	(Present for items 1 – 12)

PHAC C minutes 17th December 2015

Brendan Collins	Liverpool University	(Present for items 1 – 12)
-----------------	----------------------	----------------------------

Observers:

Emma Doohan	(Present for items 1 – 12)
Simon Ellis	(Present for items 3 – 12)

Apologies:

Jasmine Murphy	Core committee member
Harry Sumnall	Liverpool John Moores University
Simon Leigh	Liverpool John Moores University

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the second meeting on Drugs Misuse Prevention. The Committee members and attendees introduced themselves.

The Chair welcomed the members of the public to the meeting. The members of the public had been briefed already, both verbally and in writing by the NICE team, and the Chair reminded them of the protocol for members of the public, whose role is to observe (they should not speak or ask questions). No filming or recording of the meeting is permitted. The Chair reminded all present that the Committee is independent and advisory, that its decisions and recommendations to NICE do not represent final NICE guidance, and that they may be changed as a result of public consultation.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included:

- discussing the scope inclusion and exclusion criteria.
- discussing evidence review 1
- agreeing the updated evidence statements in cost effectiveness review
- discussing the draft economic modelling plan
- drafting recommendations and the committee discussion section of the guideline
- discussing opportunities for addressing any gaps in the evidence

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was in relation to 'Drug misuse prevention: targeted interventions'.

The Chair asked everyone to verbally declare any interests that they have in regard to the matter under discussion.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Janis Baird	Associate Professor of Public Health Medicine, MRC Lifecourse Epidemiology Unit	I and a group of colleagues at the MRC Lifecourse Epidemiology Unit, University of Southampton, have received funding from Danone Nutrica Early Life Nutrition for a specific research study which aims to improve the nutrition and Vitamin D status of pregnant women. <i>(25/6/15 on recruitment)</i>	Non-personal, financial, non-specific	
		I am a member of the NIHR Research for Patient Benefit South Central Advisory Committee <i>(17/12/15 at PHAC C meeting)</i>	Personal, non-financial, non-specific	
Rachel Bundock	Young People's Director, Compass	Executive Director - Compass (Voluntary sector organisation) that competitively bids to provide a range of drug prevention, early intervention, targeted and specialist substance misuse and risk taking behaviour services for children and young people across a number of local authorities. <i>(2/11/15 pre PHAC 1)</i>	Personal, non-financial, specific	
Ross	Community core	Unpaid Trustee of the Health and Race Equality	Personal, non-	

PHAC C minutes 17th December 2015

Cowan	member	Forum (HAREF), a small charity based in Newcastle which receives funding to carry out involvement and engagement activities around health and related issues.	financial, non-specific	
		Health and Wellbeing Policy Associate with Voluntary Organisations Network North East which receives funding from, and is a part of, Regional Voices, one of 21 voluntary sector networks and organisations in the DH, NHS England and Public Health England Strategic Partners Programme.	Personal, non-financial, non-specific	
David Croisdale-Appleby	Professor/Executive Chair, Standing Commission on Carers	<p>Chair of Skills for Care 2008 – 2014</p> <p>Chair of Skills for Care and Development 2008 – 2014</p> <p>Chair of Hft 2010 – 2015</p> <p>Executive Chair of the Standing Commission on Carers 2014 – present</p> <p>Chair of Dementia UK 2013 – present</p> <p>Board Member of Health Education England 2014 - present</p> <p>Board Member of Think Ahead 2014 – present</p> <p>Member, Cross-Government Council on the New Carers Strategy 2015 – present</p> <p>Professor at the School of Medicine and Health,</p>	Personal, non-financial, non-specific	

PHAC C minutes 17th December 2015

		<p>Durham University</p> <p>Professor at the Wolfson Research Institute for Health and Wellbeing</p> <p>Professor at the Durham University Business School</p> <p>Visitor/Inspector of Medical Education, General Medical Council 2001 – present</p> <p><i>(3/4/15 before PHAC)</i></p>		
Hiten Dodhia	Assistant Director Health Intelligence & Analysis/Consultant in Public Health, Southwark Council	<p>None</p> <p><i>(22/6/15 on recruitment)</i></p>		
Rose Durban	Director, RGC Consulting Ltd	<p>Through my company, RGC Consulting Ltd, I undertake some part-time work as an adviser for the DfE (Department for Education) providing children's social care advice, support and challenge to those local authorities in intervention following adverse Ofsted inspection judgement on their Children's Services arrangements.</p> <p><i>(29/10/15 pre PHAC 1)</i></p>	Personal, financial, non-specific	
Eileen Kaner	Professor of Public Health Research, Newcastle University	<p>I am a Professor of Public Health and Primary Care Research at Newcastle University and have formed conclusions, derived from evidence, on primarily alcohol and public health issues. I have also previously chaired a NICE PDG (PH24) focused on alcohol and</p>	Non-personal, non-specific, non-financial	

PHAC C minutes 17th December 2015

		<p>prevention. The work of my current PHAC has not covered these areas of my expertise. Hence I believe I have no non-pecuniary personal or professional conflicts to declare.</p> <p><i>(4/9/15 from annual declaration)</i></p>		
		<p>I am a member of the NIHR Public Health funding board.</p>	<p>Non-personal, non-specific, non-financial</p>	
		<p>I also have a number of funded studies that focus on alcohol and substance use in several of the groups focussed on including looked after children, people in criminal justice systems, people with mental health & substance use problems.</p>	<p>Personal, financial, non-specific,</p>	
		<p>I also have an alcohol research UK PhD studentship on family involved interventions for young people with substance use and mental health problems</p> <p><i>(17/12/15 from PHAC C meeting)</i></p>	<p>Non-personal, non-specific, non-financial</p>	
<p>Paul McArdle</p>	<p>Consultant Child and Adolescent Psychiatrist, Northumberland Tyne and Wear NHS Foundation Trust</p>	<p>None</p> <p><i>(29/4/15 on recruitment)</i></p>		
<p>Jim McCambri dge</p>	<p>Prof, Addictive Behaviours & Public Health, University of York</p>	<p>I have recently been awarded a research grant by NIHR-PHR to do a systematic review of novel psychoactive substances</p>	<p>Personal, non-financial, specific</p>	

PHAC C minutes 17th December 2015

		<i>(29/4/15 on recruitment)</i>		
		I have co-authored papers that may be considered as part of the evidence review for this guideline.	Personal, non-financial, specific	
Stephen Morris	Professor of Health Economics, University College London	From October 2014 to June 2015 I received consultancy fees from Health Education North Central and East London to undertake a scoping project to evaluate the future need for Speech and Language Therapists in London.	Personal, non-financial, non-specific	
		From January 2015 to July 2015 I received consultancy fees from social enterprise Oomph Wellness to undertake a pilot study to evaluate the cost-effectiveness of the Oomph! programme, which provides exercise and activity classes for older people in care homes.	Personal, non-financial, non-specific	
		From September 2011 to September 2012 I received consultancy fees from GlaxoSmithKline to undertake a cost-effectiveness analysis of mepolizumab in adults and adolescents with severe asthma.	Personal, non-financial, non-specific	
		From September 2011 to the present I have been a member of the NIHR Public Health Research Programme Research Funding Board.	Personal, non-financial, non-specific	
		From October 2014 to the present I have been a member of the NIHR Health Services and Delivery Research	Personal, non-financial, non-specific	

PHAC C minutes 17th December 2015

		Programme Funding Board.		
		From April 2015 to the present I have been a member of the NIHR Programme Grants for Applied Research expert sub-panel.	Personal, non-financial, non-specific	
Jasmine Murphy	Consultant in Public Health, Leicester City Council	None <i>(1/9/15 from annual declaration)</i>		
Kamran Siddiqi	Clinical Senior Lecturer, University of York	On behalf of my institution (University of York), I have received research funding from MRC, NIHR, CRUK (a cancer charity involved in advocacy for cancer patients), and IDRC (International Development Research Centre in Canada). <i>(7/9/15 from annual declaration)</i>	Non-personal, financial, non-specific	
		I work at the Institute of Health Sciences at University of York that has an interest in a number of public health areas of research and have secured research grants from NIHR, MRC and several other organizations for a variety of public health topics <i>(7/9/15 from annual declaration)</i>	Non-personal, financial, non-specific	
		I have a personal academic interest in a number of public health research topics including tobacco cessation, second-hand smoking, preventing tobacco uptake and ethnicity and health. I have written and	Personal, non-financial, non-specific	

PHAC C minutes 17th December 2015

		presented on these topics <i>(7/9/15 from annual declaration)</i>		
Blaine Stothard	Prevention Specialist, Blaine Stothard Consultancy	I have written journal articles and authored and co-authored book chapters on drug policy and drug prevention. I have contributed to teaching resources on drug education. I am co-editor of the journal Drugs and Alcohol Today. <i>(26/10/15 pre PHAC 1)</i>	Personal, non-financial, specific	
April Wareham	Community topic expert member	As an independent consultant trainer I have been paid by Martindale Pharma to deliver training to drug and alcohol professionals/prisons staff/policy/social workers etc. in the use of Prenoxad (naloxone hydrochloride 1mg/1ml). September 2014 to date <i>(14/8/15 from Annual Declaration)</i>	Personal, financial, non-specific	
		Director of Working with Everyone: we were contracted on a consultancy basis by Martindale Pharma to deliver a number of training sessions to Boots pre-reg pharmacists. February 2015	Personal, financial, non-specific	
		Director SMMGP: the organisation receives sponsorship for its Annual Conference from a number of organisations, including pharmaceutical companies. The organisation has received education grants from	Non-personal, financial, non-specific	

		<p>various pharmaceutical companies. Ongoing</p> <p><i>(14/8/15 from Annual Declaration)</i></p>		
<p>The contractors present at the meeting (Geoff Bates and Brendan Collins) were also asked to make any declarations of interest.</p> <p>The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.</p>				
<p>3. Minutes of last meeting</p>				
<p>The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting.</p> <p>The following was noted:</p> <ul style="list-style-type: none"> • Declarations of interest had not been noted for Hiten Dodhia. This will be added. • A point was missing in regards to previous guidance that would have had recommendations for research and whether that research happened. This will be added. <p>The Committee agreed that the minutes were a true and accurate account of the meeting otherwise.</p> <p>The Chair confirmed that all matters arising had been completed or were in hand.</p>				
<p>4. Guideline scope</p>				
<p>The Chair gave an overview of the scope of the guideline.</p> <p>The Committee discussed the key aspects and key questions from the scope and were given the opportunity to ask questions.</p> <p>Action: NICE to amend inclusion/exclusion paper</p> <p>Action: NICE to prepare a paper with related NICE guidelines</p>				
<p>5. Evidence review 1 and drafting guideline recommendations</p>				
<p>The Chair introduced Ella Novakovic, Senior Technical Analyst at NICE, who gave an overview of the evidence review plan on drugs misuse prevention.</p>				

The Committee discussed the evidence statements 1 - 19 in relation to the guideline and were given the opportunity to ask questions.

The Committee agreed to receive papers for the third committee meeting 5 days in advance instead of 10, due to time and work constraints for the NICE development team.

Action: NICE to amend evidence statements based on discussion

Action: The Committee to suggest amendments to wording of evidence statements as necessary

Action: NICE to circulate updated evidence statements for target groups 1 to 9 on 7th January for committee comment by 14th January.

Action: NICE to add glossary items to the outline guideline based on discussion

Action: NICE to draft committee discussion points for the outline guideline

The Chair thanked Ella for her presentation.

6. Updated review of cost effectiveness

The Chair introduced Geoff Bates, Researcher in Public Health Research Synthesis at Liverpool John Moores University, who gave a presentation on the updated cost effectiveness review.

The Committee discussed amendments to the updated cost effectiveness and were given the opportunity to ask questions. The committee agreed the evidence statements as final.

The Chair thanked Geoff for his presentation.

Action: LJMU to amend typo in final evidence statements.

7. Options for economic modelling including sources of data

The Chair introduced Brendan Collins, Research Fellow in Health Economics at Liverpool University, who gave a presentation on the options for economic modelling including sources of data.

The Committee discussed modelling options in relation to the guideline and were given the opportunity to ask questions.

Action: The Committee to forward any relative evidence to the NICE team to

forward to the economic contractors.

The Chair thanked Brendan for his presentation.

8. Summary of the day and next steps, including suggestions for expert testimony

The Chair summarised the discussion from the day and highlighted that the next meeting on this topic would take place on 28th January 2016.

The Committee provided suggestions for expert testimony and addressing any gaps in the evidence.

Action: The Committee to suggest any additional topic experts who may be able to provide the NICE review team with further knowledge in order to address any gaps in the evidence

Action: NICE to update the table of suggested experts and to discuss expert testimony options with the Chair for subsequent meetings.

All committee members were reminded that expenses must be submitted within 3 months of a meeting taking place.

9. Any other business

There was no other business.

Date of next meeting: 28/01/2016

Location of next meeting: NICE, London